Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
50
SLNO Quote, Financials, Valuation and Earnings
Last price:
$51.36
Seasonality move
:
21.41%
Day range:
$50.86 - $52.74
52-week range:
$41.50 - $90.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.45x
P/B ratio:
5.58x
Volume:
1.2M
Avg. volume:
2.1M
1-year change:
3.46%
Market cap:
$2.8B
Revenue:
--
EPS (TTM):
-$1.84
Analysts' Opinion
-
Consensus RatingSoleno Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $113.54, Soleno Therapeutics, Inc. has an estimated upside of 121.02% from its current price of $51.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $75.00 representing 100% downside risk from its current price of $51.37.
Fair Value
-
According to the consensus of 11 analysts, Soleno Therapeutics, Inc. has 121.02% upside to fair value with a price target of $113.54 per share.
SLNO vs. S&P 500
-
Over the past 5 trading days, Soleno Therapeutics, Inc. has overperformed the S&P 500 by 1.51% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Soleno Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Soleno Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Soleno Therapeutics, Inc. reported revenues of $66M.
Earnings Growth
-
Soleno Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Soleno Therapeutics, Inc. reported earnings per share of $0.47.
Enterprise value:
2.3B
EV / Invested capital:
4.22x
Price / LTM sales:
25.45x
EV / EBIT:
--
EV / Revenue:
23.44x
PEG ratio (5yr expected):
-0.16x
EV / Free cash flow:
-89.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$95.8M
Return On Assets:
-20.89%
Net Income Margin (TTM):
-79.5%
Return On Equity:
-26.56%
Return On Invested Capital:
-23.2%
Operating Margin:
34.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $98.7M | -- | $66M | |
| Gross Profit | -$2.2M | -$2M | $95.8M | -$500K | $64.9M | |
| Operating Income | -$32.1M | -$138.5M | -$84.3M | -$79.3M | $22.7M | |
| EBITDA | -$29.8M | -$136.5M | -$82.3M | -$78.8M | $23.2M | |
| Diluted EPS | -$3.23 | -$3.31 | -$1.84 | -$1.83 | $0.47 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $28.9M | $20.6M | $53.7M | $258.2M | $534.9M | |
| Total Assets | $42.6M | $32M | $63.5M | $296.7M | $599.9M | |
| Current Liabilities | $9M | $7.3M | $29M | $15M | $33.3M | |
| Total Liabilities | $22.4M | $16.8M | $40.3M | $32M | $105.1M | |
| Total Equity | $20.2M | $15.2M | $23.2M | $264.7M | $494.8M | |
| Total Debt | $564K | -- | $214K | $2.6M | $52M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$23.8M | -$51.4M | -$26M | -$14.9M | $43.6M | |
| Cash From Investing | -$6K | -$232.1M | -$70M | $4M | -$91.4M | |
| Cash From Financing | $56.5M | $279.5M | $294.2M | $2.3M | $218M | |
| Free Cash Flow | -$23.8M | -$51.6M | -$26M | -$15.1M | $43.6M | |
SLNO
Sector
Market Cap
$2.8B
$28.5M
Price % of 52-Week High
56.88%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-7.02%
-1.33%
1-Year Price Total Return
3.46%
-20.32%
Beta (5-Year)
-3.150
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$50.21
200-day SMA
Sell
Level
$67.01
Bollinger Bands (100)
Sell
Level
52.21 - 77.65
Chaikin Money Flow
Buy
Level
1.7M
20-day SMA
Buy
Level
$48.38
Relative Strength Index (RSI14)
Sell
Level
48.60
ADX Line
Sell
Level
19.09
Williams %R
Sell
Level
-19.3929
50-day SMA
Sell
Level
$57.54
MACD (12, 26)
Sell
Level
-1.88
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
145.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.6021)
Sell
CA Score
(Annual)
Level (-2.3986)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (3.4073)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, SLNO has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLNO average analyst price target in the past 3 months is $113.54.
-
Where Will Soleno Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Soleno Therapeutics, Inc. share price will rise to $113.54 per share over the next 12 months.
-
What Do Analysts Say About Soleno Therapeutics, Inc.?
Analysts are divided on their view about Soleno Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Soleno Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $75.00.
-
What Is Soleno Therapeutics, Inc.'s Price Target?
The price target for Soleno Therapeutics, Inc. over the next 1-year time period is forecast to be $113.54 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SLNO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Soleno Therapeutics, Inc. is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SLNO?
You can purchase shares of Soleno Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Soleno Therapeutics, Inc. shares.
-
What Is The Soleno Therapeutics, Inc. Share Price Today?
Soleno Therapeutics, Inc. was last trading at $51.36 per share. This represents the most recent stock quote for Soleno Therapeutics, Inc.. Yesterday, Soleno Therapeutics, Inc. closed at $51.37 per share.
-
How To Buy Soleno Therapeutics, Inc. Stock Online?
In order to purchase Soleno Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SLNO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SLNO
Sector
P/E ratio
--
23.75x
PEG ratio
-0.16x
-0.01x
P/B ratio
5.58x
1.83x
Price / LTM sales
25.45x
1.60x
Growth Metrics
SLNO
Sector
Revenue growth
--
4.85%
Earnings growth
125.89%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
$0.08
-$0.20
Profitability
SLNO
Sector
Profitability FY 2024
-$2M
$3.6M
Return on invested capital
-23.2%
-30.98%
Return on assets
-20.89%
-27.62%
Return on equity
-26.56%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
3
Balance Sheet
SLNO
Sector
Total cash
$498.9M
$27.2M
Short term investments
$203.5M
$25.7M
Total assets
$331M
$79.7M
Long term debt
$52M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
